Evofem Biosciences
在场
Evofem Biosciences 是一家在股票代码 EVFM (US) 下上市的公司。
涉及Evofem Biosciences的并购和融资。
- Aditxt has announced the acquisition of Evofem Biosciences (公布2023十二月14号).
高管
查看带有其 10 名主要高管的组织结构图
Evofem Biosciences 搜索最多的简介
- Saundra Pelletier, Chief Executive Officer, President and Executiv...
- Kim Kamdar, Director
- Tony O'Brien, Director
创建提醒
跟踪 Evofem Biosciences 的高管变动
生物技术
Evofem Biosciences 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Chromocell的新名称是Channel Therapeutics Corporation。 (公布2024十一月22号).
- Enveda Biosciences 刚刚宣布为 130 筹款数百万美元。 (公布2024十一月22号).
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
生物技术 行业的其他推荐联系人
消息
Evofem Biosciences 的最新新闻稿
- Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma | Tempest Therapeutics
- Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update | Tempest Therapeutics
- Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial | Tempest Therapeutics
- Tempest Extends Limited Duration Stockholder Rights Plan | Tempest Therapeutics
- Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Tempest Therapeutics
- Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs | Tempest Therapeutics
- Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference | Tempest Therapeutics
- Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Tempest Therapeutics
- Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma | Tempest Therapeutics
- Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance | Tempest Therapeutics
- View more press releases Close
通过电子邮件
